OC
CRSP icon

Oppenheimer & Co’s CRISPR Therapeutics CRSP Stock Holding History

Oppenheimer & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Sell
8,700
-529
-6% -$27.9K 0.01% 1265
2025
Q4 		$484K Buy
9,229
+549
+6% +$32.9K 0.01% 1081
2025
Q3 		$563K Sell
8,680
-299
-3% -$17.2K 0.01% 1131
2025
Q2 		$437K Sell
8,979
-495
-5% -$19.2K 0.01% 1187
2025
Q1 		$322K Sell
9,474
-2,006
-17% -$85K ﹤0.01% 1239
2024
Q4 		$452K Sell
11,480
-22,648
-66% -$1.07M 0.01% 1103
2024
Q3 		$1.6M Buy
34,128
+2,478
+8% +$126K 0.02% 618
2024
Q2 		$1.71M Buy
31,650
+1,958
+7% +$113K 0.03% 585
2024
Q1 		$2.02M Buy
29,692
+3,257
+12% +$233K 0.03% 512
2023
Q4 		$1.65M Buy
26,435
+4,437
+20% +$245K 0.03% 554
2023
Q3 		$998K Buy
21,998
+2,975
+16% +$154K 0.02% 677
2023
Q2 		$1.07M Buy
19,023
+1,079
+6% +$61.2K 0.02% 682
2023
Q1 		$812K Sell
17,944
-802
-4% -$39K 0.02% 765
2022
Q4 		$762K Sell
18,746
-1,031
-5% -$54.7K 0.02% 769
2022
Q3 		$1.29M Buy
19,777
+1,574
+9% +$114K 0.03% 572
2022
Q2 		$1.11M Buy
18,203
+1,162
+7% +$68.3K 0.02% 653
2022
Q1 		$1.07M Sell
17,041
-2,256
-12% -$142K 0.02% 721
2021
Q4 		$1.46M Sell
19,297
-1,249
-6% -$109K 0.03% 624
2021
Q3 		$2.3M Buy
20,546
+3,367
+20% +$423K 0.04% 465
2021
Q2 		$2.78M Buy
17,179
+6,635
+63% +$807K 0.05% 415
2021
Q1 		$1.28M Buy
10,544
+1,456
+16% +$220K 0.03% 617
2020
Q4 		$1.39M Sell
9,088
-263
-3% -$31.1K 0.03% 540
2020
Q3 		$782K Sell
9,351
-639
-6% -$56.7K 0.02% 669
2020
Q2 		$734K Sell
9,990
-850
-8% -$49.7K 0.02% 681
2020
Q1 		$460K Buy
10,840
+6,841
+171% +$353K 0.01% 763
2019
Q4 		$244K Buy
+3,999
New +$218K 0.01% 1105
2019
Q2 		– Sell
-7,254
Closed -$259K – 1319
2019
Q1 		$259K Buy
+7,254
New +$251K 0.01% 1100
2018
Q4 		– Sell
-6,202
Closed -$275K – 1264
2018
Q3 		$275K Buy
+6,202
New +$325K 0.01% 1101

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oppenheimer & Co's CRSP Position: Q1 2026 in Review

Oppenheimer & Co reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q1 2026, selling an estimated $27.9K and leaving 8,700 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #1265.

Oppenheimer & Co first reported a position in CRSP in Q3 2018 and has held it in 28 quarters since. The position peaked at $2.78M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Oppenheimer & Co held 8,700 shares of CRISPR Therapeutics worth $414K as of Q1 2026.
  • Oppenheimer & Co sold 529 CRISPR Therapeutics shares in Q1 2026, an estimated $27.9K.
  • CRISPR Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1265 holding.
  • Oppenheimer & Co first reported a position in CRISPR Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • Oppenheimer & Co's CRISPR Therapeutics position peaked at $2.78M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.